FDA Approves Marketing Of Plant-Derived Marijuana Medicine

GW Pharmaceuticals Epidiolex

DISTRICT OF COLUMBIA:  Regulators at the US Food and Drug Administration on Monday granted market approval to Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD) for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. The proprietary extract formulation – developed by the British biotechnology firm GW Pharmaceuticals – had Read the full article…

Study: CBD Extracts Significantly Reduced Seizure Frequency In Children With Refractory Epilepsy

Israeli researchers assessed the sustained daily use of extracted CBD oils in a cohort of young patients with treatment resistant epilepsy.

ISRAEL: The adjunctive use of CBD extracts is safe and effective in adolescent patients with refractory epilepsy, according to clinical data published online ahead of print in the journal Brain & Development. Israeli researchers assessed the sustained daily use of extracted CBD oils in a cohort of young patients with treatment resistant epilepsy. Thirty-five percent of participants experienced a Read the full article…

NY State To Hold Clinical Trials For Marijuana

An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a clinical trial for a marijuana-based drug for people under the age of 18.

NEW YORK: New York State is partnering with a British company to hold clinical trials for marijuana-based medication for children who have seizures that are resistant to their medicine. An agreement was signed Sunday between Gov. Andrew Cuomo’s administration and GW Pharmaceuticals. The state Health Department and the company will develop the framework for a Read the full article…